Abstract
The three isotypes of peroxisome proliferator-activated receptors (PPARs), PPARa, β/δ and γ, are ligand-inducible transcription factors that belong to the nuclear hormone receptor family. PPARs are implicated in the control of inflammatory responses and in energy homeostasis and thus, can be defined as metabolic and anti-inflammatory transcription factors. They exert their anti-inflammatory effects by inhibiting the induction of pro-inflammatory cytokines, adhesion molecules and extracellular matrix proteins or by stimulating the production of anti-inflammatory molecules. Furthermore, PPARs modulate the proliferation, differentiation and survival of immune cells including macrophages, B cells and T cells. This review discusses the molecular mechanisms by which PPARs and their ligands modulate the inflammatory response. In addition, it presents recent developments implicating PPAR specific ligands in potential treatments of inflammationrelated diseases, such as atherosclerosis, inflammatory bowel diseases, Parkinsons and Alzheimers diseases.
Keywords: peroxisome proliferator-activated receptors, transcription factors, molecular mechanisms, inflammatory cells, inflammatory diseases, atherosclerosis, fibrosis, cancer
Current Medicinal Chemistry
Title: PPARs in Diseases: Control Mechanisms of Inflammation
Volume: 12 Issue: 25
Author(s): Radina Kostadinova, Walter Wahli and Liliane Michalik
Affiliation:
Keywords: peroxisome proliferator-activated receptors, transcription factors, molecular mechanisms, inflammatory cells, inflammatory diseases, atherosclerosis, fibrosis, cancer
Abstract: The three isotypes of peroxisome proliferator-activated receptors (PPARs), PPARa, β/δ and γ, are ligand-inducible transcription factors that belong to the nuclear hormone receptor family. PPARs are implicated in the control of inflammatory responses and in energy homeostasis and thus, can be defined as metabolic and anti-inflammatory transcription factors. They exert their anti-inflammatory effects by inhibiting the induction of pro-inflammatory cytokines, adhesion molecules and extracellular matrix proteins or by stimulating the production of anti-inflammatory molecules. Furthermore, PPARs modulate the proliferation, differentiation and survival of immune cells including macrophages, B cells and T cells. This review discusses the molecular mechanisms by which PPARs and their ligands modulate the inflammatory response. In addition, it presents recent developments implicating PPAR specific ligands in potential treatments of inflammationrelated diseases, such as atherosclerosis, inflammatory bowel diseases, Parkinsons and Alzheimers diseases.
Export Options
About this article
Cite this article as:
Kostadinova Radina, Wahli Walter and Michalik Liliane, PPARs in Diseases: Control Mechanisms of Inflammation, Current Medicinal Chemistry 2005; 12 (25) . https://dx.doi.org/10.2174/092986705774462905
DOI https://dx.doi.org/10.2174/092986705774462905 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathogenesis of Type 1 Diabetes: Regulation of Adhesion Molecules and Immune Cell Trafficking
Current Immunology Reviews (Discontinued) A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities
Current Pharmaceutical Design COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry The Comparison of Rat and Human Intestinal and Hepatic Glucuronidation of Enterolactone Derived from Flaxseed Lignans
The Natural Products Journal Development of Small Molecule Non-peptide Formyl Peptide Receptor (FPR) Ligands and Molecular Modeling of Their Recognition
Current Medicinal Chemistry Regulation of MicroRNAs in Inflammation-Associated Colorectal Cancer: A Mechanistic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer
Current Pharmaceutical Design Role of NFAT5 in Inflammatory Disorders Associated with Osmotic Stress
Current Genomics Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics 7-prenyloxi-6-methoxycoumarin from Polygala sabulosa A.W. Bennett Regulates p38 MAPK and NF-kB Pathways Inhibiting the Inflammation Induced by Carrageenan in the Mouse Model of Pleurisy
Inflammation & Allergy - Drug Targets (Discontinued) Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design Probiotics as Biotherapeutic Agents: Present Knowledge and Future Prospects
Current Pharmaceutical Design Bacterial Translocation, Microcirculation Injury and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases
Current Medicinal Chemistry T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Potential Adverse Effects Associated with Inhibition of p38α/β MAP Kinases
Current Topics in Medicinal Chemistry Molecular Imaging and Targeted Drug Delivery Using Albumin-Based Nanoparticles
Current Pharmaceutical Design Vitamin D and Cystic Fibrosis Lung Disease
Mini-Reviews in Medicinal Chemistry Preface [Hot Topic: Therapeutic Manipulation of the Immune System: Old and New Therapeutic Approaches (Executive Editor : Emilio Jirillo)]
Current Pharmaceutical Design